TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02904174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Living Programme
Description: A 6-week Healthy Living Program (HLP) was developed and implemented for all the participants. There was one 45 minutes weekly session over 6 week. Week 1 \& 2 focused on healthy eating habits including food pyramid, balanced diet for the elderly, food labels, healthy snacks and healthy eating out. Week 3 \& 4 were about fall prevention, which included risk factors and complications of fall among older adults, preventive measures, strengthening exercises and aerobic dance. Week 5 \& 6 focused on drug management, such as knowledge on commonly used drugs, drug storage, use of analgesics and non-pharmacological pain relief strategies. Interactive activities such as games, puzzles and question \& answer session were included in the group education.
Study: NCT04758286

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emergency surgical procedures
Description: COVID-19 patients who had presented to the Emergency Department were evaluated for their emergency surgical conditions and were managed appropriately

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emergency surgical procedures
Description: COVID-19 patients who had presented to the Emergency Department were evaluated for their emergency surgical conditions and were managed appropriately
Study: NCT00700063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 Topical Gel
Description: 0.005%, three days treatment
Study: NCT03960606

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PUR1900
Description: PUR1900 contains itraconazole as the active ingredient, and it is formulated as a dry powder for oral inhalation.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PUR1900 placebo
Study: NCT03352232

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HBOT and OMT
Description: Hyperbaric oxygen therapy (HBOT) is defined as breathing 100% oxygen at increased atmospheric pressure. Osteopathic manipulative therapy (OMT) is used for myriad ailments including contractures, pain, spasticity. Patients in intervention arms will receive hyperbaric oxygen therapy at 2ATM (atmospheres) for 90minutes daily for up to 6weeks. In addition, they will receive osteopathic manipulative therapies twice a week during the same treatment phase.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HBOT and OMT
Description: Hyperbaric oxygen therapy (HBOT) is defined as breathing 100% oxygen at increased atmospheric pressure. Osteopathic manipulative therapy (OMT) is used for myriad ailments including contractures, pain, spasticity. Patients in intervention arms will receive hyperbaric oxygen therapy at 2ATM (atmospheres) for 90minutes daily for up to 6weeks. In addition, they will receive osteopathic manipulative therapies twice a week during the same treatment phase.
Study: NCT03611218

Intervention type: DEVICE
Group type: OTHER
Intervention: Dialyzer
Description: Three hemodiafiltration sessions assigned to one type of dialyzer FX P600 (Fresenius Medical Care), comparator Sureflux-17UX and comparator Polyflux 170 H
Study: NCT03835481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: Film-coated tablet
Study: NCT00700063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 Topical Gel
Description: 0.01%, three days treatment
Study: NCT02780375

Intervention type: PROCEDURE
Intervention: Blood donation during radiotherapy
Description: Participants will be asked to donate a blood sample at 5 time points before and during their radiotherapy
Study: NCT00825578

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-bronchial valve (Spiration IBV)
Description: Device: Intra-bronchial valve (Spiration IBV) The IBV is comprised of a Nitnol frame and a polymer membrane, which is held against the airway mucosa by six elastic struts and will expand and contract with airway movement during breathing. The valve is designed to conform to the size and shape of the airways. The frame has 5 flexible anchors that gently secure to the mucosal wall at a controlled depth. Valves are available in 5, 6 and 7mm diameters appropriate for different airways. During a minimally invasive procedure, a catheter is passed through a bronchoscope (a flexible tube passed into the airways through the mouth) to deploy the umbrella-shaped valves into the airways. Only flexible bronchoscopy equipment is required. The valves are designed to be removed if indicated.
Study: NCT00700063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 Topical Gel
Description: 0.015%, three days treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: three days treatment
Study: NCT03608046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab will be administered at a fixed dose of 10 mg/kg once every 2- week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab Injection
Description: Cetuximab will be administered at 400 mg/m2 loading dose week 1, 250 mg/m2 from week 2 followed by 500 mg/m2 from week 3 and irinotecan administered every 2 weeks (180 mg/m2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered every 2 weeks (180 mg/m2)
Study: NCT05534152

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sumac
Description: 1% iranian brown sumac

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sumac
Description: 1% iranian brown sumac

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sumac
Description: 1% iranian brown sumac
Study: NCT02338167

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: A blood sample will be taken during a routine blood draw

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: A blood sample will be taken during a routine blood draw
Study: NCT04190589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic extended right colectomy
Description: An extended right hemicolectomy with total mesocolic excision and meticulous central dissection as described by Hohenberger will be performed with the DaVinci Xi robot by one of two dedicated surgeons
Study: NCT01231126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Procedures were taken for induced labor delivery with misoprostol 25mcg, by vaginal rout. The pills were administered each 6 hours in a maximum number of six.
Study: NCT02692469

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Duodenal Switch
Description: Bariatric procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duodenal-ileal Bypass with Sleeve Gastrectomy
Description: Bariatric procedure
Study: NCT02333513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine/Vincristine/Procarbazine
Study: NCT01714492

Intervention type: DEVICE
Intervention: Sigma Posterior Stabilizing Rotating Platform TKA Beaded Poly
Description: Sigma PS RP TKA including a polyethylene insert with 4 beads
Study: NCT00991497

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression bandaging
Description: Cotton wool padding will then be placed over the treated vein and secured in place by crepe bandaging. An above-knee TED stocking will be applied on top of this.
Study: NCT03835481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match BI 730357
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match BI 730357
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match BI 730357
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match BI 730357
Description: Film-coated tablet
Study: NCT00529438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl
Study: NCT00140712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole Immediate Release
Description: Ropinirole Immediate Release
Study: NCT00196755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer Hydrochloride (Renagel®)
Description: Sevelamer hydrochloride three times per day with each meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium acetate (PhosLo® )
Description: Calcium acetate three times per day with each meal
Study: NCT03274011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib is a small-molecule tyrosine kinase inhibitor (TKI) that highly selectively binds to and strongly inhibits vascular en-dothelial growth factor receptor 2 (VEGFR-2), with a decrease in VEGF-mediated endothelial cell migration, proliferation, and tumor microvascular density. Previous data showed that apatinib treatment significantly improved OS and PFS with an acceptable safety profile in patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy. Our study will observe the efficacy and safety of Apatinib for recurrent or metastatic esophageal squamous cell carcinoma: A phase II, prospective, single-arm, multicenter trial.
Study: NCT00996957

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE-041
Description: Subcutaneous dose of ACE-041 approximately once every 3 weeks for a total of 4 doses. If disease stays the same or gets better, additional study drug may be offered.
Study: NCT03760198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meditoxin
Description: 50U of MEDITOXIN is injected intradermally to each axilla

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline is injected intradermally to each axilla
Study: NCT00245453

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: 250 mg tablets; 2 tablets on day 1 (500 mg load) and 1 tablet QD on days 2-5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telithromycin
Description: 400 mg tablets; 2 tablets once daily (QD) for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarythromycin
Description: 500 mg extended release tablets; 2 tablets QD for 7 days
Study: NCT01169701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus was supplied in boxes with 60 tablets. Available tablets: 1.0 mg, 0.5 mg and 0.25 mg.
Study: NCT01169701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus was administrated as Prograf® or Advagraf®, but could not be changed during study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus was administrated as Prograf® or Advagraf®, but could not be changed during study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA)
Description: Myfortic® (MFS) was given as 720-1440 mg/day or 360-1440 mg/day. Cell-Cept® (MMF) was given as 1000-2000 mg/day or 500-2000 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic acid (MPA)
Description: Myfortic® (MFS) was given as 720-1440 mg/day or 360-1440 mg/day. Cell-Cept® (MMF) was given as 1000-2000 mg/day or 500-2000 mg/day.
Study: NCT00786968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: laronidase
Description: 1.74 mg intrathecally every 1-3 months for 1 year
Study: NCT00631813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 0.5 mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 1 mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 2 mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: bid
Study: NCT01479751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Patients receive MgSO4 50 mg/kg for 10 min before injection of Roc 0.6 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: patients receive ketamine 0.5 mg/kg 2 min before Roc injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium
Description: Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.
Study: NCT03786926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-689
Description: HMPL-689 is a PI3Kδ inhibitor
Study: NCT03047915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: The intervention consists of listening to a choice of music for 30 to 60 minutes on a loaned iPad with disposable headphones.
Study: NCT02614092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water-based Activity + Cognitive Training
Description: This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
Study: NCT03279159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jaluronius CS cream short term evaluation
Description: Short term evaluation to investigate the hydrating activity of a single application of the study product on the forearms (volar surface) after repeated stripping procedure,measured immediately after stripping execution (T0i), 1,8 and 24 hour/s after product application (T1h, T8h and T24h).
Study: NCT03872310

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STARSTIM
Description: Right DLPC was located as F4 according to the international 10-20 EEG system. Anodal tDCS was delivered with the anodal pole on the right DLPFCand the cathodal pole on the left cheek of the participant to avoid contaminating other brain regions during electrical stimulation via a pair of rubber electrodes housed in saline-soaked sponge coverings (5x5 cm\^2). The direct current was applied with 1.5 mA for 15 min which can facilitate visual short-term memory and create an excitatory effect for up to 90 min. The anodal tDCS stimulated the right DLPC for 15 min with 1.5 mA in active tDCS condition. The sham tDCS condition followed identical tDCS protocol and same 15-min duration except the stimulation time only lasted for the initial 30s so that the participants felt the same initial tingling sensation (if any, only in some participants) but without the actual stimulation. The investigators will perform assessments of adverse effects after each session by a standardized questionnaire.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: STARSTIM
Description: Right DLPC was located as F4 according to the international 10-20 EEG system. Anodal tDCS was delivered with the anodal pole on the right DLPFCand the cathodal pole on the left cheek of the participant to avoid contaminating other brain regions during electrical stimulation via a pair of rubber electrodes housed in saline-soaked sponge coverings (5x5 cm\^2). The direct current was applied with 1.5 mA for 15 min which can facilitate visual short-term memory and create an excitatory effect for up to 90 min. The anodal tDCS stimulated the right DLPC for 15 min with 1.5 mA in active tDCS condition. The sham tDCS condition followed identical tDCS protocol and same 15-min duration except the stimulation time only lasted for the initial 30s so that the participants felt the same initial tingling sensation (if any, only in some participants) but without the actual stimulation. The investigators will perform assessments of adverse effects after each session by a standardized questionnaire.
Study: NCT02487069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HSCT from MSD
Description: HSCT from MSD is the first choice for the patients who have HLA-matched sibling donors.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HSCT from MUD
Description: HSCT from MUD is the second choice for the patients who don't have HLA-matched sibling donors but have HLA-matched unrelated donors.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HSCT from HRD
Description: HSCT from HRD is the choice for the patients who have neither HLA-matched sibling donors nor HLA-matched unrelated donors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: CsA is used in all the patients for GVHD prophylaxis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: CsA is used in all the patients for GVHD prophylaxis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: CsA is used in all the patients for GVHD prophylaxis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: MTX is used in all the patients for GVHD prophylaxis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: MTX is used in all the patients for GVHD prophylaxis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: MTX is used in all the patients for GVHD prophylaxis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin
Description: ATG is used in the patients receiving HSCT from MUD and HRD for GVHD prophylaxis.In MUD group,total ATG doses is 7 mg/kg;In HRD group,total ATG doses is 7.5 or 10 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin
Description: ATG is used in the patients receiving HSCT from MUD and HRD for GVHD prophylaxis.In MUD group,total ATG doses is 7 mg/kg;In HRD group,total ATG doses is 7.5 or 10 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: MMF is used in the patients receiving HSCT from MSD and HRD for GVHD prophylaxis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: MMF is used in the patients receiving HSCT from MSD and HRD for GVHD prophylaxis.
Study: NCT01991301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzumib
Description: carfilzumib will be added to the standard regimen of drugs for prevention of graft-versus-host disease.
Study: NCT02994316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Copeptine dosage in children with diabetic ketoacidosis at diagnosis
Description: Blood collection of 3 mL for copeptin dosage will be taken at different times in the first hours of management of diabetic ketoacodosis in children under the age of 16 years

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Copeptine dosage in children with diabetic ketoacidosis at diagnosis
Description: Blood collection of 3 mL for copeptin dosage will be taken at different times in the first hours of management of diabetic ketoacodosis in children under the age of 16 years
Study: NCT03279159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jaluronius CS cream long term evaluation
Description: Long term evaluation to investigate the hydrating activity of the repeated application of the study product on the face (twice a day, for an uninterrupted period of 8 weeks), measured at basal visit (T0) and after 4 and 8 week-treatment (T4, T8)
Study: NCT00354536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK716155 subcutaneous injections
Description: albiglutide subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Description: placebo injection
Study: NCT03591835

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight+6
Description: For the Tochen formula in Group 1, ETT depth will be calculated by taking the infant's actual weight within the last 24 h and adding 6 cm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NTL+1
Description: The infants in Group 2 will be intubated by measuring the NTL, the distance from the basement of the nasal septum to the the tragus of the ear. Measurements will be recorded as centimeters.
Study: NCT02231528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of ultrasound with active GPS
Description: CVC insertion with ultrasound with active GPS function and appropriate needles

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of ultrasound with inactive GPS
Description: CVC insertion with ultrasound with inactive GPS function and conventional needles
Study: NCT02411084

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Begelomab
Description: BEGEDINA® (Begelomab) is a murine immunoglobulin G (IgG) 2b monoclonal antibody against CD26 (dipeptidyl peptidase-4; DPP4) and is produced by biotechnological means.
Study: NCT00721500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A
Description: contact lens
Study: NCT01625416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care Management
Description: All patients randomized to receive the stepped care management procedures will meet with the trauma support specialist (TSS) prior to discharge from the hospital, who will provide coaching on use of mobile technology for mental health concerns. The TSS will complete follow-up correspondence across the 3-6 month time period to assess mental health functioning and use of information technology that addresses medical concerns. Patients who report barriers to mHealth technologies and request additional therapeutic services for mental health concerns assistance will receive evidence-based motivational interviewing and cognitive behavioral intervention procedures that can span up to 3-6 months.
Study: NCT00721500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A
Description: contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A
Description: contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A
Description: contact lens
Study: NCT02411084

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Second-line Treatment
Description: There are no approved second-line treatments for aGvHD and due to the life-threatening nature of the disease it was agreed with the FDA and EMA that BEGEDINA® would be compared with best conventional second-line treatments which will be chosen by each center, based on the clinical conditions of the individual subject and according to the standard practice at the study center and which may vary between centers. Treatments are generally biological products and could include anti-thymocyte globulin, monoclonal antibodies, such as anti-CD147, basiliximab, daclizumab and alemtuzumab; mycophenolate mofetil; anti-TNF-alpha; pentostatin; dinileukin diftitox; N-acetyl-cysteine; sirolimus; and visulizumab.